Specimen Reference Sets
Visit the Application Form for EDRN Reference Sets.
Read the EDRN Pre/Validation Reference Set Specimen Sharing Guidelines.
| Organ | Protocol ID | Reference set title | Cases | Controls | Total participants | Participants groups | Specimen type | Number of specimens | Volume range (mL) | Specimens at NCI-F? | Sequential samples? | Follow-up data? | Pathology | Image files avail? | Incidental cancer? |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bladder | 234 | 191 | 425 | | Serum | 2,554 | 0.03–0.05 | | | | | | | ||
| | |
|
| | | | DNA from blood | | | | | | | | |
| | |
|
| | | | Urine DNA | | | | | | | | |
| Breast | 30 | 62 | 92 | BBD that progressed to cancer BBD controls | Tissue slides | 9,256 | "each" | No, at Kansas | N/A | | ✓ | ✓ | ✓ | ||
| | |
|
| | | | | | | | | | | | |
| Breast | 262 | 570 | 832 | Pre-diagnosis specimens, DCIS cases, Invasive cancer cases, LCIS cases, Benign→later cancer cases, Normal→later cancer cases, Benign Disease Atypia controls, Benign Disease non-Atypia controls, Normal controls | Serum | 16,444 | 0.01–0.8 | ✓ | | | ✓ | ✓ | ✓ | ||
| | |
|
| | | | Plasma | 16,169 | 0.01–0.9 | | | | | | |
| | |
|
| | | | | | | | | | | | |
| Ovarian & Breast | 441 | 95 | 536 | Cases (pooled), controls (pooled) | Serum | 105 sets | 0.3 | ✓ | | | | | | ||
| | |
|
| | | | | | | | | | | | |
| Colon | 50 | 100 | 150 | | Serum | 2,100 | 0.3 | ✓ | | | | | | ||
| | |
|
| | | | Plasma | 1500 | 0.3 | | | | | | |
| | |
|
| | | | Urine | 150 | 5 | | | | | | |
| | |
|
| | | | | | | | | | | | |
| HEDS | Hepatocellular carcinoma Early Detection Strategy study (HEDS) |
114 | 1609 | 1723 | N/A | Serum | 45,605 | 0.100-5.0 | ✓ | ✓ | ✓ | | | | |
| | |
|
| | | N/A | Plasma | 46,727 | 0.100-5.0 | | | | | | |
| | |
|
| | | N/A | DNA | 1,264 | 0.1-.05 | | | | | | |
| Liver | 50 | 50 | 100 | | Serum | 1,329 | 0.01–0.5 | ✓ | | | | | ✓ | ||
| | |
|
| | | | Plasma | 731 | 0.2–0.5 | | | | | | |
| | |
|
| | | | | | | | | | | | |
| Liver | 427 | 432 | 871 | | Serum | 10,815 | 0.01–1.0 | ✓ | | | | | | ||
| | |
|
| | | | Plasma | 5,090 | 0.2–0.5 | | | | | | |
| | |
|
| | | | | | | | | | | | |
| Lung | 193 | 92 | 286 | | Serum | 4,257 | 0.05–0.5 | ✓ | | ✓ | A few data elements | ✓ | at 1 time point | ||
| | |
|
| | | | Plasma | 4,286 | 0.05–2.0 | | | | | | |
| Lung | Lung Ref Set A Phase 2 Validation (retrospective) |
268 | 309 | 577 | | Serum | 3,695 | 0.025–0.5 | ✓ | | | | | | |
| | |
|
| | | | Plasma | 5,267 | 0.15–0.3 | | | | | | |
| Lung | 86 | 147 | 233 | | Plasma | 3,846 | 0.025–0.375 | ✓ | | | | | | ||
| Lung | 159 | 195 | 354 | | Serum | 6,430 | 0.015–0.2 | ✓ | | | | | | ||
| | |
|
| | | | Plasma | 6,787 | 0.01–0.175 | | | | | | |
| | |
|
| | | | | | | | | | | | |
| Pancreas | 100 | 155 | 255 | | Serum | 4,847 | 0.1–0.8 | ✓ | | | ✓ | | | ||
| | |
|
| | | | Plasma | 3,006 | 0.2–0.8 | | | | | | |
| | |
|
| | | | | | | | | | | | |
| Prostate | 341 | 559 | 900 | | Serum | 16,778 | 0.075–0.5 | ✓ | | | | | ✓ | ||
| | |
|
| | | | Buffy coat | 864 | 0.05–0.5 | | | | | | |
| | |
|
| | | | Whole urine | 771 | 1.2–5.0 | | | | | | |
| | |
|
| | | | EDTA plasma | 13,137 | 0.1 | | | | | | |
| | |
|
| | | | Sediment/RNALater | 738 | 0.035–1.5 | | | | | | |
| | |
|
| | | | Sediment/PBS | 486 | 0.01–0.4 | | | | | | |
| | |
|
| | | | Supernatant | 1,493 | 2.5–50 | | | | | | |
| | |
|
| | | | PAXGene | 1,716 | "tubes" | | | | | | |
| | |
|
| | | | | | | | | | | | |
| Pancreas | 48 | 270 | 318 | | Serum | 16,958 | 0.1–0.3 | ✓ | | | | | ✓ | ||
| | |
|
| | | | EDTA plasma | 8,605 | 0.1–0.3 | | | | | | |
| | |
|
| | | | EUS cystic fluid | 5,538 | 0.05–0.1 | | | | | | |
| | |
|
| | | | Surgical cystic fluid | 4,599 | 0.1–0.6 | | | | | | |